Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ultragenyx Pharmaceutical revenue
Ultragenyx Pharmaceutical's revenue is $560.2 million.
What is Ultragenyx Pharmaceutical's revenue?
- Ultragenyx Pharmaceutical's revenue growth from 2016 to 2024 is 421,125.56%.
- Ultragenyx Pharmaceutical has 893 employees, and the revenue per employee ratio is $627,357.
- Ultragenyx Pharmaceutical's peak quarterly revenue was $164.9M in 2024(q4).
- Ultragenyx Pharmaceutical peak revenue was $560.2M in 2024.
- Ultragenyx Pharmaceutical annual revenue for 2023 was 434.2M, 19.52% growth from 2022.
- Ultragenyx Pharmaceutical annual revenue for 2024 was 560.2M, 29.01% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Ultragenyx Pharmaceutical historical revenue
Ultragenyx Pharmaceutical's peak revenue was $560.2M in 2024. The peak quarterly revenue was $164.9M in 2024(q4).
Ultragenyx Pharmaceutical's revenue increased from $133.0k in 2016 to $560.2M currently. That's a 421,125.56% change in annual revenue.
Ultragenyx Pharmaceutical annual revenue
Ultragenyx Pharmaceutical annual revenue over time
| Fiscal year / year | Ultragenyx Pharmaceutical revenue |
|---|---|
| 2016 | $133,000 |
| 2017 | $2.6M |
| 2018 | $51.5M |
| 2019 | $103.7M |
| 2020 | $271.0M |
| 2021 | $351.4M |
| 2022 | $363.3M |
| 2023 | $434.2M |
| 2024 | $560.2M |
Rate Ultragenyx Pharmaceutical's financial transparency
Ultragenyx Pharmaceutical annual growth
Ultragenyx Pharmaceutical saw the greatest revenue growth in 2018, when revenue increased by 1,871.48%.
Ultragenyx Pharmaceutical had the lowest revenue growth in 2022, when revenue changed by 3.39%.
Ultragenyx Pharmaceutical annual growth rate over time
| Year | Ultragenyx Pharmaceutical growth |
|---|---|
| 2017 | 1864%↑ |
| 2018 | 1871%↑ |
| 2019 | 101%↑ |
| 2020 | 161%↑ |
| 2021 | 30%↑ |
| 2022 | 3%↑ |
| 2023 | 20%↑ |
| 2024 | 29%↑ |
Ultragenyx Pharmaceutical quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Ultragenyx Pharmaceutical quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2016 | - | $17,000 | $111,000 | $5,000 |
| 2017 | - | - | $198,000 | $2.4M |
| 2018 | $10.7M | $12.8M | $11.8M | $16.3M |
| 2019 | $18.2M | $24.1M | $25.8M | $35.6M |
| 2020 | $36.3M | $61.7M | $81.5M | $91.5M |
| 2021 | $99.4M | $87.0M | $81.6M | $83.4M |
| 2022 | $79.9M | $89.3M | $90.7M | $103.3M |
| 2023 | $100.5M | $108.3M | $98.1M | $127.4M |
| 2024 | $108.8M | $147.0M | $139.5M | $164.9M |
Ultragenyx Pharmaceutical jobs nearby
Do you work at Ultragenyx Pharmaceutical?
Is Ultragenyx Pharmaceutical transparent about its revenue structure?
Ultragenyx Pharmaceutical financial information
| CEO | Emil D. Kakkis |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 893 |
| Date Founded | 2010 |
| Headquarters | Novato, California |
| Number of Locations | 6 |
| Revenue | $560.2M |
| Net Income | -$707,421,000 |
| Gross Proft | $483.5M (2024) |
| PE Ratio | -4.73 |
| Tax Rate | -0.0% |
| Market Capitalization | $2.7B |
| Total Assets | $1,545,444,000 |
| Ticker | RARE |
Ultragenyx Pharmaceutical jobs you might like
Ultragenyx Pharmaceutical financing
Ultragenyx Pharmaceutical received early financing of $45.0M on 2011-06-20.
| Series | Round size | Date |
|---|---|---|
| Series A | $45M | 06/2011 |
| Series B | $75M | 12/2012 |
| Post Ipo Equity | $65M | 06/2016 |
Ultragenyx Pharmaceutical investors
| Investors | Security type |
|---|---|
| Pappas Ventures | Series A |
| HealthCap | Series A |
| F Prime Capital | Series A |
| TPG Biotech | Series A |
| Pappas Ventures | Series B |
| HealthCap | Series B |
| TPG Growth | Series B |
| Adage Capital Management | Series B |
| F Prime Capital | Series B |
| BlackRock Private Equity Partners | Series B |
| Takeda Pharmaceutical | Post Ipo Equity |
| Takeda Ventures Inc | Post Ipo Equity |
Ultragenyx Pharmaceutical competitors
Ultragenyx Pharmaceutical's top competitor, Pelican Expression Technology, earned an annual revenue of $39.1M.
Ultragenyx Pharmaceutical's smallest competitor is Sesen Bio with revenue of $19.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Cerexa Inc. | - | $1.3M | 29 | - |
| Pelican Expression Technology | - | $39.1M | 71 | - |
| Cara Therapeutics | - | $7.1M | 84 | - |
| Chimerix | - | $212,000 | 82 | - |
| Dimension Therapeutics | - | $11.5M | 59 | - |
| FibroGen | - | $29.6M | 461 | - |
| Theraclone Sciences | - | $470,000 | 2 | - |
| Spectrum Pharmaceuticals | - | $10.1M | 235 | - |
| Raptor Pharmaceuticals | - | - | 125 | - |
| Sesen Bio | - | $19.6M | 35 | - |
Ultragenyx Pharmaceutical revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Ultragenyx Pharmaceutical highest paying jobs
Zippia gives an in-depth look into the details of Ultragenyx Pharmaceutical, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ultragenyx Pharmaceutical. The employee data is based on information from people who have self-reported their past or current employments at Ultragenyx Pharmaceutical. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ultragenyx Pharmaceutical. The data presented on this page does not represent the view of Ultragenyx Pharmaceutical and its employees or that of Zippia.
Ultragenyx Pharmaceutical may also be known as or be related to ULTRAGENYX PHARMACEUTICAL INC., Ultragenyx Pharmaceutical, Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc. and Ultragenyx Pharmaceutical, Inc.